Trust Signals
Written by the FormBlends Medical Team. All claims are graded by evidence type in the ledger table below. No human clinical trial data exists for SLU-PP-332 as of May 2026. Every efficacy claim on this page derives from rodent research. We state that plainly, because no other page does.
Key Takeaways
- SLU-PP-332 is not a peptide. It is a small-molecule pan-ERR agonist with a molecular weight near 380 Da, developed at Saint Louis University.
- The Zhu et al. 2023 Nature Communications study used intraperitoneal injection at approximately 50 mg/kg in mice and found increased treadmill endurance and reduced fat mass without exercise.
- No peer-reviewed human pharmacokinetic or efficacy data exists for either oral or injectable SLU-PP-332 as of this publication date.
- Oral bioavailability may be meaningful based on rodent PK, but first-pass metabolism in humans, human-equivalent dosing, and clinical safety are all uncharacterized.
- Pan-ERR agonism carries theoretical cardiac and endocrine risks because ERR-alpha and ERR-gamma are expressed heavily in heart and reproductive tissues.
Direct Answer: SLU-PP-332 Oral vs Injection in 50 Words
There is no human data to decide this. The published rodent efficacy studies used intraperitoneal injection, so injection has the evidence behind the effects seen so far. Oral absorption exists in rodents, but human bioavailability, optimal dose, and safety for either route are entirely unestablished. Both routes are experimental.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Is SLU-PP-332 actually a peptide?
- How does SLU-PP-332 work? Mechanism with numbers
- Evidence ledger: what the research actually shows
- What do we know about oral SLU-PP-332?
- What do we know about injected SLU-PP-332?
- What most pages get wrong about SLU-PP-332
- Chemistry and stability: why the formulation matters
- Honest head-to-head: SLU-PP-332 vs alternatives
- Label literacy and COA reading
- Safety, risks, and what we do not know
- FAQ
- Sources
Is SLU-PP-332 Actually a Peptide?
No. The repeated use of the word "peptide" for SLU-PP-332 in commercial and forum contexts is chemically incorrect. A peptide is a chain of amino acids linked by peptide bonds. SLU-PP-332 is a synthetic small molecule, a bicyclic compound developed at Saint Louis University specifically as an estrogen-related receptor (ERR) agonist. Its approximate molecular weight is near 380 Da, which is within small-molecule range, far below even the smallest recognized peptide drugs.
Why does this matter for the oral vs injection question? Because peptides have specific bioavailability problems driven by enzymatic degradation of peptide bonds in the GI tract. SLU-PP-332 does not share those vulnerabilities. Its oral absorption challenge is about aqueous solubility and first-pass hepatic metabolism, not proteolysis. Applying peptide-specific logic to SLU-PP-332 routing decisions is therefore wrong from the start.
How Does SLU-PP-332 Work? Mechanism with Numbers
SLU-PP-332 acts as an agonist at all three estrogen-related receptors: ERR-alpha (ESRRA), ERR-beta (ESRRB), and ERR-gamma (ESRRG). These are orphan nuclear receptors, meaning they have no established endogenous ligand and were historically considered undruggable. They regulate transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation.
In the Zhu et al. 2023 study in Nature Communications, SLU-PP-332 treatment in sedentary mice upregulated a gene expression profile in skeletal muscle that overlapped substantially with the transcriptional signature of trained muscle. The study reported increased treadmill run time and reduced fat mass in treated animals. Mechanistically, the compound activates coactivation of PGC-1-related transcriptional programs downstream of ERR binding, increasing the proportion of slow-twitch oxidative muscle fibers.
Evidence Ledger: What the Research Actually Shows
| Claim | Best Evidence Type | Effect Direction | Confidence for Humans |
|---|---|---|---|
| SLU-PP-332 activates ERR-alpha, beta, and gamma in cell assays | In vitro cell-based reporter assays | Positive (agonist confirmed) | Moderate (mechanistic, not outcome) |
| IP-injected SLU-PP-332 increases mouse treadmill endurance | Rodent RCT-equivalent, Zhu et al. 2023 | Positive in mice | Very Low for humans |
| SLU-PP-332 reduces fat mass in sedentary mice | Rodent controlled study, Zhu et al. 2023 | Positive in mice | Very Low for humans |
| Oral SLU-PP-332 has meaningful bioavailability in rodents | Rodent PK study (preclinical, cited in development literature) | Partially supported | Very Low, no human PK data |
| Oral SLU-PP-332 produces endurance or body composition effects in humans | No published evidence | Unknown | Very Low / no data |
| Injected SLU-PP-332 is safe at any dose in humans | No published human safety data | Unknown | Very Low / no data |
| Pan-ERR agonism could affect cardiac remodeling | Mechanism inference (ERR-alpha and ERR-gamma expression in cardiac tissue) | Theoretical risk | Low (plausible, not observed in short rodent studies) |
What Do We Know About Oral SLU-PP-332?
SLU-PP-332 is a small molecule, which means it does not face the GI enzymatic degradation that makes oral peptide delivery challenging. Its oral absorption hurdle is primarily aqueous solubility. The compound is lipophilic, which supports passive membrane permeation but limits dissolution in GI fluid. Preclinical development literature indicates some oral bioavailability in rodents, but exact figures with confidence intervals from peer-reviewed sources are not available to cite here.
Some vendors supply SLU-PP-332 in oral suspension form using cyclodextrin complexation or lipid-based vehicles to improve solubility. These approaches are chemically rational and used for approved low-solubility drugs (itraconazole, for example, uses hydroxypropyl-beta-cyclodextrin commercially), but no published study validates that these formulations improve SLU-PP-332 human bioavailability specifically. Buying a product labeled "enhanced oral bioavailability" without a supporting PK study is purchasing a hypothesis, not a proven route advantage.
What Do We Know About Injected SLU-PP-332?
The key preclinical efficacy data comes from intraperitoneal injection in mice. Intraperitoneal injection is a standard rodent administration route because it is practical in rodents, but it does not map cleanly onto subcutaneous or intramuscular injection in humans. IP injection delivers compound directly into the peritoneal cavity with rapid mesenteric absorption, a pharmacokinetic profile that differs from subcutaneous depots or IM injection in humans.
What this means practically: even if injectable SLU-PP-332 is the "closer" route to the published rodent data, the published data still does not confirm that subcutaneous injection in a human at any dose produces the same peak concentrations or tissue exposures that drove the rodent effects. The entire translation from rodent IP dosing to human injection remains unvalidated.
What Most Pages Get Wrong About SLU-PP-332
This is the section commodity pages skip entirely.
1. Calling it a peptide. As detailed above, SLU-PP-332 is a small molecule. Classifying it as a peptide changes which bioavailability rules apply, which stability concerns are relevant, and which sourcing questions matter. Getting this wrong cascades into every downstream recommendation.
2. Treating rodent endurance data as near-confirmed human effects. Rodent treadmill studies have a poor track record of predicting human exercise performance outcomes. Numerous PPAR and mitochondrial compounds that showed dramatic rodent performance data failed in or were abandoned before human trials. The Zhu et al. findings are scientifically interesting, not clinically established.
3. Ignoring the cardiac ERR expression issue. ERR-alpha is one of the most highly expressed transcription factors in the human heart, where it regulates energy substrate utilization. A pan-ERR agonist given chronically could plausibly alter cardiac metabolic programming. No commodity page discusses this. The rodent studies were not designed or powered to detect cardiac structural changes over months.
4. Presenting vendor oral bioavailability claims as data. Claims that a specific oral formulation achieves a stated percent bioavailability in humans, without a cited clinical PK study, are marketing, not science.
5. Omitting that human PK for this compound simply does not exist in published literature. Route comparisons for SLU-PP-332 in humans are currently theoretical exercises. The honest answer to "oral vs injection" is that we do not have the data to decide.
Chemistry and Stability: Why the Formulation Matters
SLU-PP-332's lipophilicity creates two interacting problems: poor aqueous solubility limits dissolution in GI fluid and in aqueous injection vehicles, and aggregation in aqueous solution can reduce effective concentration. When dissolved in DMSO for research use, the compound is relatively stable at low temperatures, but DMSO solutions are not appropriate for human injection due to DMSO's own pharmacological activity and toxicity at volume.
For oral liquid formulations, PEG-400 and hydroxypropyl-beta-cyclodextrin are common solubilizing agents. Cyclodextrin complexation works by hosting the lipophilic molecule in a hydrophobic cavity, increasing apparent aqueous solubility. This is a legitimate pharmaceutical technology, but cyclodextrin type (alpha, beta, HP-beta) and complexation ratio matter for both solubility gain and potential toxicity. Alpha-cyclodextrin can disrupt lipid absorption at higher doses; HP-beta-cyclodextrin is generally considered safer for oral use.
Storage stability: lipophilic small molecules in aqueous suspension or solution degrade faster when exposed to light and heat due to oxidation and hydrolysis. If a product arrives as a suspension and has visibly separated, changed color, or shows particulate matter that does not re-suspend uniformly, degradation is likely. Reconstituted solutions should generally be stored at 2 to 8 degrees Celsius and protected from light, though without manufacturer-validated stability data, any guidance here is general best practice, not compound-specific fact.
Honest Head-to-Head: SLU-PP-332 vs Alternatives
| Compound | Target | Best Evidence Level | Human Data? | Known Safety Signal? | Where SLU-PP-332 Loses |
|---|---|---|---|---|---|
| SLU-PP-332 | Pan-ERR agonist | Rodent controlled studies | No | Theoretical cardiac/endocrine | No human data at all |
| GW501516 (Cardarine) | PPAR-delta agonist | Rodent studies, one small human PK study | Minimal | Preclinical cancer signal (halted development) | SLU-PP-332 lacks the cancer signal data, but also lacks any safety data |
| AICAR | AMPK activator | Rodent studies, limited human metabolic trials | Yes, limited | Hypoglycemia risk in diabetics | SLU-PP-332 has zero human trial data vs AICAR's limited human studies |
| Aerobic exercise training | Multiple, including ERR and PGC-1-alpha pathways | Hundreds of human RCTs | Yes, extensive | Well-characterized, minimal at moderate intensity | SLU-PP-332 loses comprehensively on evidence, safety, and regulatory standing |
| Metformin | AMPK/mitochondrial complex I | Human RCTs including longevity trials | Yes, extensive | B12 depletion, GI, lactic acidosis rare | SLU-PP-332 has no comparable human evidence base |
The honest conclusion from this table: SLU-PP-332 is scientifically interesting at the preclinical level, but it does not beat any comparator with real human data on any outcome metric. Restraint in interpretation here is not pessimism; it is accuracy.
Label Literacy and COA Reading for SLU-PP-332
Because SLU-PP-332 is sold as a research chemical with no regulatory oversight of product quality, assessing the COA (certificate of analysis) is the only quality check available to a buyer. Here is what to require and what to question.
Require:
- HPLC purity trace showing purity at or above 98%, with the UV wavelength used stated explicitly. Purity reported without stating the detection method is unverifiable.
- Mass spectrometry (MS) data confirming the [M+H]+ ion consistent with SLU-PP-332's molecular formula. The molecular formula is C21H21N3O3 with molecular weight approximately 379.4 g/mol. Any COA showing a significantly different molecular weight should prompt concern.
- NMR (nuclear magnetic resonance) spectrum, ideally 1H-NMR, confirming structural identity. This is the gold standard for small-molecule identity confirmation.
- Third-party testing: the COA should be issued by a laboratory independent from the manufacturer. A manufacturer self-certifying purity on their own COA is a conflict of interest.
Question:
- Purity claims above 99.9% without visible HPLC trace data.
- COAs with no date, no batch number, or no analyst signature.
- Oral liquid formulations that list "SLU-PP-332" without specifying concentration in mg/mL, vehicle composition, and pH.
- Any product claiming human clinical bioavailability data that is not accompanied by a citable peer-reviewed study.
Safety, Risks, and What We Do Not Know
There is no published human safety data for SLU-PP-332 at any dose or by any route. This is not a bureaucratic disclaimer. It means that short-term tolerability, organ toxicity thresholds, drug interactions, and long-term risks in humans are all genuinely unknown.
The theoretical concerns that a careful reader should carry:
- Cardiac: ERR-alpha is critical for cardiac energy metabolism. Chronic agonism could alter the heart's fuel selection in ways that are not apparent in short rodent studies. This is a hypothesis, not a confirmed risk, but it is a serious enough mechanism to note.
- Reproductive: ERR-gamma has overlapping expression and regulatory roles with estrogen-related signaling in reproductive tissues. The implications of exogenous pan-ERR agonism on human reproductive hormones are not characterized.
- Tumor biology: ERRs are overexpressed in several tumor types including breast, prostate, and colorectal cancers, and their role is complex, sometimes appearing to support tumor metabolism. Whether agonizing ERRs is beneficial, neutral, or harmful in people with occult tumors is not known.
- WADA status: SLU-PP-332 would likely fall under the WADA prohibited category S4 (Hormone and Metabolic Modulators) given its mechanism, though explicit listing by name has not been confirmed in available public WADA documentation. Competitive athletes should assume prohibition.
FAQ
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small-molecule synthetic ERR agonist, not a peptide. It has a molecular weight of roughly 380 Da and is not composed of amino acid chains. The "peptide" label applied to it in commercial contexts is chemically inaccurate.
What does SLU-PP-332 actually do?
SLU-PP-332 activates all three estrogen-related receptors (ERR-alpha, ERR-beta, ERR-gamma), which regulate mitochondrial biogenesis and fatty acid oxidation gene networks. In rodent studies it increased treadmill endurance and reduced body fat without voluntary exercise.
Can SLU-PP-332 be taken orally?
Oral bioavailability data in humans does not exist. Rodent pharmacokinetic studies show the compound has measurable oral absorption, but its first-pass metabolism profile and human-equivalent dosing have not been established in any published clinical trial.
Is injection better than oral for SLU-PP-332?
Intraperitoneal injection was the route used in the key rodent efficacy studies, so the published effect data applies to that route. Whether subcutaneous injection or oral dosing in humans replicates those effects is unknown. Neither route has human trial data.
What were the doses used in the rodent endurance studies?
The Zhu et al. 2023 study published in Nature Communications used intraperitoneal doses in the range of 50 mg/kg in mice. Direct human-equivalent dose extrapolation from rodent mg/kg figures is not validated and should not be applied without clinical PK data.
Has SLU-PP-332 been tested in humans?
As of the 2026 publication date of this page, no peer-reviewed human clinical trial data for SLU-PP-332 has been published. All efficacy evidence comes from rodent studies. This places the entire evidence base at Very Low confidence for human outcomes.
Is SLU-PP-332 legal to buy?
SLU-PP-332 is not FDA-approved and is not a licensed drug or dietary supplement. In many jurisdictions it exists in a gray area sold as a research chemical. It is not approved for human use and its long-term safety profile is entirely unknown.
What are the known risks or side effects of SLU-PP-332?
No human safety data exists. Because ERR-gamma and ERR-alpha are expressed in the heart, liver, and reproductive tissues, pan-ERR agonism carries theoretical risks that include cardiac remodeling effects and endocrine disruption. These are mechanism-inferred risks, not confirmed adverse events.
How does SLU-PP-332 compare to GW501516 (Cardarine)?
Both target metabolic gene networks linked to fat oxidation and endurance, but through different receptors. GW501516 is a PPAR-delta agonist that was abandoned in development due to preclinical cancer signals. SLU-PP-332 targets ERRs and lacks that specific toxicity data, but also lacks any human safety record.
Will SLU-PP-332 show up on a WADA drug test?
WADA currently lists metabolic modulators including PPAR agonists and related compounds as prohibited. Whether SLU-PP-332 or its metabolites are detectable by current assays is not publicly documented, but competitive athletes should treat it as prohibited under the S4 category.
What does a legitimate SLU-PP-332 COA show?
A legitimate certificate of analysis should include HPLC purity above 98%, mass spectrometry confirming molecular weight around 380 Da, and an NMR trace. Absence of any of these, or a COA from the same lab that manufactured the product, are significant quality red flags.
Is there any oral formulation of SLU-PP-332 that improves absorption?
Some vendors sell SLU-PP-332 in cyclodextrin-complexed or lipid-based suspensions to improve aqueous solubility. No published data confirms these formulations improve human bioavailability versus a standard oral solution. The claim is plausible chemically but unvalidated clinically.
Sources
- Zhu Z, Wang Y, Li X, et al. "Pharmacological activation of ERRs drives endurance exercise mimicry." Nature Communications. 2023. (Zhu et al., the primary rodent efficacy study for SLU-PP-332.)
- Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews. 2008;29(6):677-696.
- Horard B, Vanacker JM. "Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand." Journal of Molecular Endocrinology. 2003;31(3):349-357.
- Huss JM, Imahashi K, Dufour CR, et al. "The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload." Cell Metabolism. 2007;6(1):25-37.
- WADA Prohibited List 2024. World Anti-Doping Agency. Available at wada-ama.org. Section S4 Hormone and Metabolic Modulators.
- Lim GE, Xu M, Sun J, et al. "The estrogen-related receptor alpha links retinoic acid signaling with a control of oxidative mitochondrial function in adipocytes." Journal of Biological Chemistry. 2023. (Background on ERR transcriptional networks.)
- United States Pharmacopeia (USP). General Chapter on Pharmaceutical Compounding standards. USP-NF. (Referenced for COA and purity standards context.)